Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of Hetrombopag Olamine in Healthy Subjects
NCT06346925Phase 1Not yet recruiting
- Sponsor
- Hengrui
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hetrombopag in immune thrombocytopenia (ITP) and aplastic anemia (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Timepoint and 1 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)aplastic anemia
Beyond the preview
Go deeper on NCT06346925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346925.